Page last updated: 2024-11-12

1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one: from Curcuma longa; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10904292
CHEMBL ID482607
CHEBI ID176637
SCHEMBL ID3294805
MeSH IDM0445698

Synonyms (6)

Synonym
CHEBI:176637
(1e,4e,6e)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one
(1e,4e,6e)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one
1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one
CHEMBL482607
SCHEMBL3294805

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Promising properties, including long-circulation time, enhanced tumor localization, interference with "multidrug" resistance effects, and environmental biodegradability, often result in an improvement of the drug bioavailability and effectiveness."( Antiproliferative effect of ASC-J9 delivered by PLGA nanoparticles against estrogen-dependent breast cancer cells.
Colombo, M; Corsi, F; Gramatica, F; Marinozzi, MR; Mazzucchelli, S; Morasso, C; Pandolfi, L; Prosperi, D; Vanna, R; Verderio, P, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylheptanoidA family of plant metabolites with a common 1,7-diphenylheptane structural skeleton, carrying various substituents. They are mainly distributed in the roots, rhizomes and bark of Alpinia, Zingiber, Curcuma and Alnus species.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1154169Cytotoxicity against human KB cells assessed as growth inhibition by resazurin microplate assay2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis, cytotoxicity against human oral cancer KB cells and structure-activity relationship studies of trienone analogues of curcuminoids.
AID466922Cytotoxicity against HEK293 cells after 16 hrs by alamar blue assay2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species.
AID335876Protection against beta-amyloid (1 to 42) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay2002Journal of natural products, Sep, Volume: 65, Issue:9
Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer's disease.
AID466918Antitrypanosomal activity against diminazene-resistant Trypanosoma brucei brucei deltaTbat1-KO after 48 hrs by alamar blue assay2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species.
AID466921Antileishmanial activity against Leishmania mexicana MNYC/BZ/62/M379 amastigotes after 48 hrs by alamar blue assay2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species.
AID466917Antitrypanosomal activity against Trypanosoma brucei brucei 427 after 48 hrs by alamar blue assay2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species.
AID1154172Ratio of curcumin IC50 to compound IC50 for human KB cells assessed as growth inhibition by resazurin microplate assay2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis, cytotoxicity against human oral cancer KB cells and structure-activity relationship studies of trienone analogues of curcuminoids.
AID335875Protection against beta-amyloid (25 to 35) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay2002Journal of natural products, Sep, Volume: 65, Issue:9
Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer's disease.
AID466920Antileishmanial activity against Leishmania major Friedlin promastigotes after 48 hrs by alamar blue assay2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species.
AID515080Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 24 hrs by microtiter alamar blue assay2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity.
AID1154170Cytotoxicity against african green monkey Vero cells by green fluorescent protein detection method2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis, cytotoxicity against human oral cancer KB cells and structure-activity relationship studies of trienone analogues of curcuminoids.
AID466919Antitrypanosomal activity against multidrug-resistant Trypanosoma brucei brucei B48 after 48 hrs by alamar blue assay2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species.
AID1154171Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for human KB cells2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis, cytotoxicity against human oral cancer KB cells and structure-activity relationship studies of trienone analogues of curcuminoids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (9.30)29.6817
2010's35 (81.40)24.3611
2020's4 (9.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.38 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index5.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.33%)5.53%
Reviews2 (4.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (93.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]